ATE490336T1 - Verfahren zur verbesserten isolierung rekombinant produzierter proteine - Google Patents

Verfahren zur verbesserten isolierung rekombinant produzierter proteine

Info

Publication number
ATE490336T1
ATE490336T1 AT06725404T AT06725404T ATE490336T1 AT E490336 T1 ATE490336 T1 AT E490336T1 AT 06725404 T AT06725404 T AT 06725404T AT 06725404 T AT06725404 T AT 06725404T AT E490336 T1 ATE490336 T1 AT E490336T1
Authority
AT
Austria
Prior art keywords
recombinantly produced
produced proteins
improved isolation
protein
peptone
Prior art date
Application number
AT06725404T
Other languages
English (en)
Inventor
Stefan Winge
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35063154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE490336(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Application granted granted Critical
Publication of ATE490336T1 publication Critical patent/ATE490336T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/647Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06725404T 2005-03-29 2006-03-29 Verfahren zur verbesserten isolierung rekombinant produzierter proteine ATE490336T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102475A EP1707634A1 (de) 2005-03-29 2005-03-29 Verfahren zur Isolierung von rekombinant hergestellten Proteinen
PCT/EP2006/061148 WO2006103258A1 (en) 2005-03-29 2006-03-29 Method for improved isolation of recombinantly produced proteins

Publications (1)

Publication Number Publication Date
ATE490336T1 true ATE490336T1 (de) 2010-12-15

Family

ID=35063154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06725404T ATE490336T1 (de) 2005-03-29 2006-03-29 Verfahren zur verbesserten isolierung rekombinant produzierter proteine

Country Status (10)

Country Link
US (2) US9388402B2 (de)
EP (4) EP1707634A1 (de)
AT (1) ATE490336T1 (de)
DE (1) DE602006018587D1 (de)
DK (1) DK1863920T3 (de)
ES (1) ES2354715T3 (de)
PL (1) PL1863920T3 (de)
PT (1) PT1863920E (de)
SI (1) SI1863920T1 (de)
WO (1) WO2006103258A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101681A1 (en) * 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US8088900B2 (en) * 2006-03-30 2012-01-03 Novo Nordisk A/S Two-phase precipitation of proteins
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
EP1988101A1 (de) * 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
ES2364118T3 (es) 2007-07-11 2011-08-25 Novo Nordisk A/S Purificación de factor viii usando una resina de modo mixto o multimodal.
EP2027875A1 (de) * 2007-08-23 2009-02-25 Octapharma AG Verfahren zur Isolierung und Reinigung eines prionenproteinfreien Target-Proteins
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858A (zh) * 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
ES2538706T3 (es) * 2008-06-24 2015-06-23 Octapharma Ag Procedimiento de purificación del factor de coagulación VIII
US9120873B2 (en) 2008-08-21 2015-09-01 Octapharma Ag Recombinantly produced human factor VIII and IX
CN102387784B (zh) * 2008-10-21 2014-04-02 巴克斯特国际公司 冻干的重组vwf配方
RU2731720C2 (ru) 2010-03-30 2020-09-08 Октафарма Аг Способ очистки витамин к-зависимых белков, таких как коагуляционный фактор vii
MX2012011065A (es) 2010-03-30 2012-10-10 Octapharma Ag Proceso para purificacion de proteina de factor de crecimiento.
DK2563904T3 (en) 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium
JP6282467B2 (ja) 2010-10-05 2018-02-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー タンパク質を生産するための方法
EP4353743A2 (de) 2011-05-13 2024-04-17 Octapharma AG Verfahren zur erhöhung der produktivität eukaryotischer zellen bei der herstellung von rekombinantem fviii
WO2012173260A1 (ja) 2011-06-17 2012-12-20 学校法人東日本学園・北海道医療大学 ループスアンチコアグラント検出用血液凝固時間の測定方法
KR101439634B1 (ko) * 2012-10-26 2014-09-15 주식회사 바이오에프디엔씨 항균펩타이드 베타 디펜신 3 및 그 유사체의 재조합 단백질로의 대량 생산 방법
WO2015021423A2 (en) * 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
TW201738256A (zh) * 2016-04-04 2017-11-01 日產化學工業股份有限公司 蛋白質產生方法
EP3625329A1 (de) 2017-05-17 2020-03-25 Octapharma AG Verfahren zur herstellung eines rekombinanten zielproteins
CN107470012B (zh) * 2017-07-05 2020-04-07 昆明理工大学 一种磷灰石纯矿物的提取方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
PL3884463T3 (pl) * 2018-11-30 2024-04-29 Amgen Inc. Systemy i sposoby do wykrywania efektu cytopatycznego w komórkach
CN111208239B (zh) * 2020-02-25 2022-10-18 浙江工业大学 一种键合态香气物质的除杂纯化方法
CN111793595A (zh) * 2020-07-23 2020-10-20 上海奥浦迈生物科技有限公司 一种hek293细胞无血清培养基
CN115299584B (zh) * 2022-08-10 2024-04-02 广东省广盐集团股份有限公司 一种具有减盐效果的盐微粒的制备方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
DE122004000028I1 (de) 1984-01-12 2004-09-30 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
ATE74164T1 (de) 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (de) 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
DK155388C (da) 1986-07-08 1989-10-23 Palle Pedersen Laas
ATE63335T1 (de) 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
NO872932L (no) 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US4980456A (en) 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
EP0294910B1 (de) 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
HUT64591A (en) 1989-11-17 1994-01-28 Novo Nordisk As Protein complexes with viii/c factor activity and process for their production
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO2000049147A1 (en) 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
US6338964B1 (en) * 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
IL148060A0 (en) * 1999-08-25 2002-09-12 Immunex Corp Compositions and methods for improved cell culture
CA2404163C (en) 2000-03-22 2009-09-29 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
WO2005058930A2 (en) * 2003-12-11 2005-06-30 Proteomtech Inc. Methods for production of recombinant vascular endothelial cell growth inhibitor

Also Published As

Publication number Publication date
EP1707634A1 (de) 2006-10-04
US20170183703A1 (en) 2017-06-29
US9388402B2 (en) 2016-07-12
ES2354715T3 (es) 2011-03-17
US10626431B2 (en) 2020-04-21
DE602006018587D1 (de) 2011-01-13
EP1863920B1 (de) 2010-12-01
SI1863920T1 (sl) 2011-03-31
EP3467116A1 (de) 2019-04-10
DK1863920T3 (da) 2011-03-14
EP2258860A1 (de) 2010-12-08
PL1863920T3 (pl) 2011-05-31
EP1863920A1 (de) 2007-12-12
WO2006103258A1 (en) 2006-10-05
US20090088370A1 (en) 2009-04-02
PT1863920E (pt) 2011-01-19

Similar Documents

Publication Publication Date Title
ATE490336T1 (de) Verfahren zur verbesserten isolierung rekombinant produzierter proteine
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
WO2019139645A3 (en) High efficiency base editors comprising gam
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
EA201100146A1 (ru) Растения, имеющие улучшенные характеристики урожайности, и способ их получения
DE69838383D1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
PE20070796A1 (es) Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2395091A3 (de) Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu deren Herstellung
DK1422237T3 (da) Fremgangsmåder til rekombinant frembringelse af antifusogene peptider
DK1929001T3 (da) Nye dehydrogenaser, disses derivater og en fremgangsmåde til fremstilling af optisk aktive alkanoler
EP2189534A3 (de) Pflanzen mit SYT-Polypeptid transformiert die unter abiotischem Stress einen erhöhten Ertrag aufweisen und Methoden zur Herstellung dieser Pflanzen
EP2599870A3 (de) Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
AR054599A1 (es) Proteccion de la proteina krp mutante negativa dominante contra una inhibicion activa del complejo cdk -ciclina por la krp de tipo salvaje
MX2012003451A (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para prepararlas.
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
DK1495112T3 (da) Cellekulturmedium
EP2998401A3 (de) Pflanzen mit verbesserten ertragseigenschaften und verfahren zur herstellung davon
AR070143A1 (es) Gen de bacillus thuringiensis (bt) con actividad contra coleopteros
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
EA202091496A1 (ru) Вариант инсектицидного гена axmi115 и способы его применения
ATE451457T1 (de) Verfahren zur dipeptidherstellung
WO2004013333A3 (de) Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1863920

Country of ref document: EP